Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 887 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: EPOCH II Clear all

Conditions: Glioblastoma Multiforme
Interventions: TLN-4601; Drug
Lead sponsor: Thallion Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: New York, New York • Durham, North Carolina

Conditions: Non-Small Cell Lung Cancer
Interventions: Gedatolisib, Paclitaxel, Carboplatin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Alzheimer Disease
Interventions: Intermittent theta burst stimulation active coil, Sham coil; Device
Lead sponsor: HealthPartners Institute; Other
Eligibility: 40 Years to 90 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Seasonal Allergic Rhinitis
Interventions: Nasal CO2, Inactive Placebo Gas; Drug
Lead sponsor: Capnia, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Gait Disorders, Neurologic
Interventions: droxidopa; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 30 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: West Bloomfield, Michigan

Conditions: Cancer-related Cognitive Difficulties
Interventions: Ibuprofen, Home-Based Exercise, Placebo; Drug · Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Neuroendocrine Tumors
Interventions: Bevacizumab, Temozolomide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteer, Major Depressive Disorder, Depression
Interventions: Ketamine, Placebo, Cobot TS MV robotic arm for TMS, NeurOptics PLRTM-30000 Pupillometer; Drug · Other · Device
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: docetaxel, erlotinib hydrochloride; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 65 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 3
States / cities: Los Angeles, California • Seattle, Washington

Conditions: Suicide, Suicidal Ideation
Interventions: STAT-PC, YST-III; Other
Lead sponsor: Elizabeth Arnold; Other
Eligibility: 18 Years to 24 Years
Enrollment: 1,485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Austin, Texas • Dallas, Texas

Conditions: Leukemia, Lymphoma
Interventions: Focus Group, Internet-Based Intervention, Interview; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 39 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer
Interventions: Capecitabine; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 3
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: Chronic Myelomonocytic Leukemia
Interventions: 5-Azacitidine; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Buffalo, New York • Portland, Oregon • Salt Lake City, Utah

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Questionnaire Administration, Tin Sn 117m Pentetate; Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Diabetic Macular Edema
Interventions: RO7446603, Aflibercept, Faricimab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 70
States / cities: Phoenix, Arizona • Springdale, Arkansas • Campbell, California + 60 more

Conditions: Previously Treated Metastatic Colorectal Cancer
Interventions: SGI-110 Dose Escalation, Regorafenib, TAS-102, SGI-110, Irinotecan; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Baltimore, Maryland • New York, New York

Conditions: Kidney Transplantation in Highly Sensitized Patients
Interventions: Imlifidase; Drug
Lead sponsor: Hansa Biopharma AB; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Anal Dysplasia, Human Papilloma Virus, HIV
Interventions: imiquimod, ablative; Drug · Procedure
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years and older · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Gallbladder Cancer
Interventions: irinotecan hydrochloride; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 20
States / cities: Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 17 more

Conditions: Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Atezolizumab, Tocilizumab, Tiragolumab; Biological
Lead sponsor: Alain Algazi; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatocellular Carcinoma
Interventions: Zanzalintinib, Durvalumab, Tremelimumab; Drug
Lead sponsor: Anwaar Saeed; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • San Antonio, Texas

Conditions: Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Interventions: Tucatinib, Eribulin, Trastuzumab; Drug
Lead sponsor: Criterium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Albuquerque, New Mexico + 3 more

Conditions: Hypovolemia
Interventions: Kedbumin 25%, Normal Saline Solution; Drug
Lead sponsor: Kedrion S.p.A.; Industry
Eligibility: Up to 12 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 2
States / cities: Louisville, Kentucky • Milwaukee, Wisconsin

Conditions: CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
Interventions: Subcutaneous Blinatumomab; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Morgantown, West Virginia

Search by objective public record fields.

Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme

Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)

TMS Pilot in Early AD II

The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis

Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease

The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care

Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

Capecitabine For Nasopharyngeal Cancer

A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia

Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation

Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV

Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients

Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)